Comprehensive Oral Diabetes Medication Resource 2022

Abstract

Get full access to this article

View all access options for this article.

References

Heerspink

HJL

Stefansson

Correa-Rotter

, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446. doi:10.1056/NEJMoa2024816

Lalau

J-D

Farshad

Bennis

Hurtel-Lemaire

A-S

Belpaire

De Broe

. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41:547-553. doi:10.2337/dc17-2231

McMurray

JJV

Solomon

Inzucchi

, et al. Dapagliflozin in patients with HF and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. doi:10.1056/NEJMoa1911303

Perkovic

Jardine

Neal

, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. doi:10.1056/NEJMoa1811744

Rosenstock

Kahn

Johansen

, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patient with type 2 diabetes. JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772

Wiviott

Raz

Bonaca

, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357. doi:10.1056/NEJMoa1812389

Zinman

Wanner

Lachin

, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi:10.1056/NEJMoa1504720